Loading
LianBio Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 22 Aug 2022.
LianBio: what insiders have been doing
LianBio, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). LianBio has had no insider filing for more than a year; the last one goes back to 11 April 2024.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
19
Thresholds
n/a
Buy Volume
€4M
5 ops. · all time
Sell Volume
€10,272
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
US$0.04
Analyst consensus
Income statement
EBITDA-US$124.3M
Net income-US$110.3M0.0% margin
Valuation
P/Book0.0x
Beta0.13
Balance sheet & cash
Market capUS$4.5M
Total debtUS$4.3M
Free Cash Flow-US$101M
Debt / Equity1%
Profitability & ownership
ROE-32.4%
ROA-21.7%
% insiders0.0%
% institutions7.5%
Last declaration on 11 April 2024
Declarations19 total
36,300 shares@ US$2.520.1% of flowOrdinary SharesSEC:0001062993-24-003732:0
36,300 shares@ US$2.5216.9% of flowOrdinary SharesSEC:0001831283-24-000011:0
36,300 shares@ US$2.52100.0% of flowOrdinary SharesSEC:0001831283-24-000010:0
36,300 shares@ US$2.52100.0% of flowOrdinary SharesSEC:0001062993-24-003733:0
36,300 shares@ US$2.52100.0% of flowOrdinary SharesSEC:0001062993-24-003729:0
224,005 shares0Ordinary SharesSEC:0001831283-23-000054:0
224,005 shares0Ordinary SharesSEC:0001831283-23-000053:0
907,498 shares0Ordinary SharesSEC:0001831283-23-000052:0
2,239 shares@ US$1.6532100.0% of flowOrdinary SharesSEC:0001831283-23-000002:0
998,240 shares@ US$2.403.5% of flowAmerican Depositary SharesSEC:0001062993-22-018544:0
Canonical exit: 16 Nov 2022 (T+90)
69,000 shares@ US$3.134.7% of flowAmerican Depositary SharesSEC:0001062993-22-013616:0
Canonical exit: 24 Aug 2022 (T+90)
8,700 shares@ US$2.490.5% of flowAmerican Depositary SharesSEC:0001062993-22-013535:0
Canonical exit: 21 Aug 2022 (T+90)
36,548 shares@ US$6.4971.1% of flowOrdinary SharesSEC:0000899243-22-000135:0
69,588 shares0Ordinary SharesSEC:0000899243-22-000126:0
2,250,000 shares@ €13.817687.9% of flowOrdinary SharesSEC:0001062993-21-010295:0
Canonical exit: 1 Feb 2022 (T+90)
120,000 shares@ US$15.5037.5% of flowOrdinary SharesSEC:0000899243-21-042807:0
Canonical exit: 30 Jan 2022 (T+90)
19 of 19 declarations
About LianBio
LianBio is a U.S.-listed biotechnology company that was built around a cross-border development model focused on China and other major Asian markets. The company was associated with the NASDAQ market in the United States, and its corporate footprint was centered in Princeton, New Jersey, with historical ties to Shanghai as well. From a strategy standpoint, LianBio positioned itself as a regional development and licensing platform rather than a traditional fully integrated pharmaceutical manufacturer. Its core idea was to identify innovative drug candidates and enabling technologies, secure rights through partnerships, and advance those assets clinically and commercially in Asia. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1831283/000183128324000004/lianbio-pressreleasexstrat.htm?utm_source=openai))
Operationally, LianBio’s business lines were organized around partnered pipeline assets across multiple therapeutic areas, including oncology, immunology, cardiovascular disease, and other high-unmet-need indications. The company’s value proposition was built on sourcing differentiated science from global innovators and then using local regulatory and development expertise to unlock value in its target geographies. In that sense, LianBio functioned as a regionally focused biotech development engine, with an emphasis on licensing, clinical advancement, and geographic rights management rather than large-scale in-house manufacturing or broad commercial infrastructure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1831283/000183128323000126/adr-20230930.htm?utm_source=openai))
Read moreShow less
A major inflection point came in February 2024, when LianBio announced the completion of a strategic review and decided to begin winding down operations. The announcement included plans to sell remaining pipeline assets, reduce headcount substantially, delist its ADSs from NASDAQ, and deregister under the Exchange Act. The company also said it would retain only a core workforce needed to manage an orderly wind-down and maximize value from its remaining business and assets. For equity investors, this is a critical distinction: the company shifted from a development-stage biotech story to a liquidation and asset-monetization case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1831283/000183128324000004/lianbio-pressreleasexstrat.htm?utm_source=openai))
From a market and geography perspective, LianBio remained a United States company even though its strategic focus was largely Asian. That dual identity mattered: the company was U.S.-listed, operated from Princeton, New Jersey, and pursued value creation primarily through Asia-centric assets and partnerships. After the 2024 wind-down decision, the company indicated that trading may continue, if at all, on OTC Markets after the NASDAQ delisting process, highlighting a material reduction in liquidity and visibility versus a normal listed biotech. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1831283/000183128324000004/lianbio-pressreleasexstrat.htm?utm_source=openai))
The most important recent development is therefore not a product launch or a pipeline expansion, but the orderly exit from operations and the disposal of remaining assets. For investors, LianBio should be viewed as a company in advanced restructuring mode, with the investment case centered on residual asset value, execution risk around the wind-down, and the timing of any monetization events. In the absence of clear public evidence of a strategic reversal, the company’s story is best understood as one of managed contraction rather than growth. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1831283/000183128324000004/lianbio-pressreleasexstrat.htm?utm_source=openai))
